Jana Schlenzka

机构：Heidelberg University, University Hospital Heidelberg

发表论文 27 篇 · 总被引 443 次 · h-index 11

代表论文

• Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE (2020 · Leukemia · 被引 67)
• A systematic classification of death causes in multiple myeloma (2018 · Blood Cancer Journal · 被引 44)
• Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma (2021 · Blood Cancer Journal · 被引 33)
• Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial (2021 · Blood · 被引 30)
• Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial (2024 · The Lancet Haematology · 被引 20)
• Cyclophosphamide‐based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial Re LA psE (2017 · European Journal Of Haematology · 被引 20)